Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.1200-0.0500 (-2.30%)
At close: 04:00PM EDT
2.1900 +0.07 (+3.30%)
After hours: 06:41PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 243.22M
Enterprise value 464.61M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.74
Price/book (mrq)N/A
Enterprise value/revenue 1.54
Enterprise value/EBITDA -2.91

Trading information

Stock price history

Beta (5Y monthly) 0.56
52-week change 3-52.47%
S&P500 52-week change 326.49%
52-week high 35.6300
52-week low 31.4300
50-day moving average 32.2350
200-day moving average 32.9372

Share statistics

Avg vol (3-month) 32.26M
Avg vol (10-day) 32.17M
Shares outstanding 5114.73M
Implied shares outstanding 6114.73M
Float 895.43M
% held by insiders 11.39%
% held by institutions 176.03%
Shares short (30 Apr 2024) 421.69M
Short ratio (30 Apr 2024) 413.18
Short % of float (30 Apr 2024) 422.35%
Short % of shares outstanding (30 Apr 2024) 419.11%
Shares short (prior month 28 Mar 2024) 423.45M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -19.64%
Operating margin (ttm)-41.43%

Management effectiveness

Return on assets (ttm)-17.26%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)301.87M
Revenue per share (ttm)2.94
Quarterly revenue growth (yoy)137.60%
Gross profit (ttm)N/A
EBITDA -156.63M
Net income avi to common (ttm)-59.29M
Diluted EPS (ttm)-0.7400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)259.78M
Total cash per share (mrq)2.26
Total debt (mrq)481.16M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.17
Book value per share (mrq)-0.72

Cash flow statement

Operating cash flow (ttm)-152.92M
Levered free cash flow (ttm)-19.51M